BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 11/21/2017
Entire Document
 

 
BioLineRx Ltd.
APPENDIX TO CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS
(UNAUDITED)
 
   
Nine months ended
September 30,
 
   
2016
   
2017
 
   
in USD thousands
 
             
Adjustments required to reflect net cash used in operating activities:
           
Income and expenses not involving cash flows:
           
Depreciation and amortization
   
368
     
381
 
Long-term prepaid expenses
   
4
     
(8
)
Interest and exchange rate differences on short-term deposits
   
(277
)
   
(439
)
Share-based compensation
   
959
     
1,309
 
Warrant issuance costs
   
-
     
17
 
Exchange differences on cash and cash equivalents
   
(60
)
   
(307
)
Loss (gain) on adjustment of warrants to fair value
   
(179
)
   
316
 
     
815
     
1,269
 
                 
Changes in operating asset and liability items:
               
Decrease (Increase) in prepaid expenses and other receivables
   
14
     
(362
)
Increase in accounts payable and accruals
   
299
     
1,865
 
     
313
     
1,503
 
     
1,128
     
2,772
 
                 
Supplementary information on interest received in cash
   
310
     
378
 
Supplementary non-cash investment (see Note 4b)
   
-
     
2,985
 

11